A Phase 1, Randomized, Placebo-Controlled, Double-Blind, Dose-Escalation Study to Evaluate Safety, Tolerability and Pharmacokinetics of Single Doses of Q203 in Normal, Healthy, Male and Female Volunteers

Trial Profile

A Phase 1, Randomized, Placebo-Controlled, Double-Blind, Dose-Escalation Study to Evaluate Safety, Tolerability and Pharmacokinetics of Single Doses of Q203 in Normal, Healthy, Male and Female Volunteers

Completed
Phase of Trial: Phase I

Latest Information Update: 08 Dec 2016

At a glance

  • Drugs Q 203 (Primary)
  • Indications Tuberculosis
  • Focus Adverse reactions
  • Sponsors Qurient Co
  • Most Recent Events

    • 01 Aug 2016 Status changed from active, no longer recruiting to completed.
    • 30 Mar 2016 Planned End Date changed from 1 Mar 2016 to 1 May 2016 as reported by ClinicalTrials.gov.
    • 21 Jan 2016 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top